Search
-
Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics
(European Respiratory Journal, 2022-05-26)Article de revueOpen access -
Association between COVID-19 infection and work exposure assessed by the Mat-O-Covid job exposure matrix in the CONSTANCES cohort
(Occupational and Environmental Medicine, 2022-09-20)Article de revueOpen access -
Evolution of Anxiety Disorder Prevalence and Associated Factors in First Responders in Both the Medium and Long Terms after the January 2015 Terrorist Attacks in France
(Depression and Anxiety. vol. 2023, 2023-09-11)Article de revueOpen access -
Changes in dynamic arterial elastance induced by volume expansion and vasopressor in the operating room: a prospective bicentre study
(Annals of intensive care. vol. 9, n° 1, pp. 117, 2019-10)Article de revueOpen access -
Decongestant use and the risk of myocardial infarction and stroke: a case-crossover study
(Scientific Reports. vol. 11, n° 1, pp. 4160, 2021-02-18)Article de revueOpen access -
Differential Patterns of Domain-Specific Cognitive Complaints and Awareness Across the Alzheimer's Disease Spectrum
(Frontiers in Aging Neuroscience. vol. 14, 2022-06-16)Article de revueOpen access -
Effects of mechanical in-exsufflation in preventing postextubation acute respiratory failure in intensive care acquired weakness patients: a randomized controlled trial
(Critical Care Science. vol. 35, n° 2, pp. 168-176, 2023-04-01)Article de revueOpen access -
Parental mental health and reporting of their child's behaviour: measurement invariance of the French version of the parental strengths and difficulties questionnaire
(European Child and Adolescent Psychiatry, 2024-02-25)Article de revueRequest a copy -
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide
(Molecular Cancer. vol. 23, n° 1, pp. 38, 2024-02-20)Article de revueOpen access -
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
(Journal of Hematology and Oncology. vol. 15, n° 1, pp. 149, 2022-10-21)Article de revueOpen access